• TechCrunch
• CrunchBase
• More
  • TechCrunch UK
  • TechCrunch France
  • TechCrunch Japan

Selecta Biosciences

edit

Selecta Biosciences is a biopharmaceutical company developing the first generation of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Our proprietary product platform technology combines recent advances in immunobiology with cutting-edge nanotechnology to develop targeted immunomodulatory nanoparticles.

Milestones

edit

• 
  Selecta Biosciences added David Siewers as Vice President Finance.
  Posted 8/16/10 at 6:14pm
• 
  Selecta Biosciences added Werner Cautreels as President and CEO.
  Posted 8/16/10 at 6:14pm
• 
  Selecta Biosciences received $22M in Series D funding. (2/13/12)
  Posted 2/13/12 at 3:18am via onbiovc.com
• 
  Selecta Biosciences received $47.3M in Unattributed funding. (10/27/11)
  Posted 10/27/11 at 7:31pm via fiercebiotech.com
• 
  Selecta Biosciences received $3M in Grant funding. (8/17/10)
  Posted 8/19/10 at 10:02pm via finsmes.com
• 
  Selecta Biosciences received $15M in Series C funding. (4/5/10)
  Posted 4/5/10 at 10:49am via freshnews.com
• 
  Selecta Biosciences received $15.1M in Series B funding. (2/25/09)
  Posted 4/14/09 at 10:01am via selectabio.com

Videos

Screenshots

edit

Sources

1. Selecta Biosciences, Inc. Closes $15.1M Series B Financing (selectabio.com) [edit]
2. SELECTA CLOSES $15 MILLION SERIES C FINANCING (freshnews.com) [edit]
3. Selecta Biosciences Receives $3M Grant (finsmes.com) [edit]
4. Russian fund leads $94.5M investment in two Langer biotechs (fiercebiotech.com) [edit]
5. Selecta Biosciences, Inc.: Series D $22M (onbiovc.com) [edit]